Eunyoung Park

CEO at AinB

Presenter

Eunyoung Park is the Founder & CEO of AinB, an AI-native biotechnology company developing the ALT:D platform for AI-driven antibody drug discovery. She holds a Ph.D. in Cancer Biology from the University of Texas at Austin and brings over 15 years of antibody drug development experience spanning the full development lifecycle — from target selection through regulatory strategy. Prior to founding AinB, she held roles at Samsung Bioepis, where she worked on the regulatory affairs team, and ABL Bio, where she led bispecific antibody development through IND filing. She was also part of the team at Standigm, an AI drug design company. Eunyoung founded AinB in 2022 to bridge the gap between generative AI and experimentally validated antibody discovery, combining deep biological domain expertise with AI-driven platform development.